Skip to main content

IQVIA guidance

  • IQV · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$263.99−0.28%Close 17 Nov 2026 · Market value $42.86B

In its results release of 27 Oct 2026 (Q3 FY2026), IQVIA gave 3 forecasts in figures, among them revenue of $17.35B to $17.50B for FY2026. Over the last two years, results landed above the company's own last range 1 of 4 times, within it 3 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 27 Oct 2026

MeasurePeriodGuidanceAs stated
Revenue · RaisedFY2026$17.35B to $17.50BThe company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be between $12.90 and $13.00.
EPS · AdjustedFY2026$12.90 to $13.00The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be between $12.90 and $13.00.
EBITDA · AdjustedFY2026$4.03B to $4.05BThe company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be between $12.90 and $13.00.

Source: the company's earnings release.

Guidance against results above 1 · within 3 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$17.35B to $17.50BRaised twice—To come
EPS · AdjustedFY2026$12.90 to $13.00Raised 3 times—To come
EBITDA · AdjustedFY2026$4.03B to $4.05BRaised twice—To come
RevenueFY2025$16.15B to $16.25BRaised once$16.31BAbove the range
EBITDA · AdjustedFY2025$3.77B to $3.80BLowered once$3.79BWithin the range
RevenueFY2024$15.35B to $15.40BGiven once$15.40BWithin the range
EBITDA · AdjustedFY2024$3.67B to $3.70BGiven once$3.68BWithin the range

IQV in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.